Thomson Reuters names most promising drugs of 2015
Posted: 24 March 2015 |
The Intellectual Property and Science business of Thomson Reuters has released the 2015 edition of its annual Drugs to Watch report…
The Intellectual Property and Science business of Thomson Reuters, the world’s leader in intelligent information for businesses and professionals, has released the 2015 edition of its annual Drugs to Watch report.
The study reveals a significant increase in the number of expected blockbusters from three drugs in 2014 to eleven in 2015. Three of the new drugs are expected to reach over $3 billion in sales by 2019. Thomson Reuters analysts utilized CortellisTM Competitive Intelligence—the pharmaceutical industry’s leading source for drug pipeline, deals, patents, and company content—to forecast the new-to-market drugs expected to lead the pack in sales and potentially emerge as blockbusters (earning $1 billion+) by 2019.
Thomson Reuters’ annual forecast finds significant increase in the number of blockbusters set to enter this year’s market
The analysis spotlights the following 11 potential blockbusters, ranked by highest sales forecast (U.S. $ billions):
| Drugs to Watch | Company | Therapy Area | 2019 Sales Forecast in U.S. $ billions |
| Opdivo (nivolumab) | Bristol-Myers Squibb | Melanoma | 5.684 |
| Praluent (alirocumab) | Regeneron Pharmaceuticals and Sanofi | Hypercholesterolemia | 4.414 |
| LCZ-696 (sacubitril and valsartan) | Novartis | chronic heart failure | 3.731 |
| Ibrance (palbociclib) | Pfizer | breast cancer | 2.756 |
| lumacaftor plus ivacaftor | Vertex Pharmaceuticals | cystic fibrosis | 2.737 |
| Viekira Pak (veruprevir, ritonavir, ombitsvir and dasabuvir) | AbbVie | hepatitis C | 2.5 |
| evolocumab | Amgen and Astellas Pharma | hypercholesterolemia/ hypherlipidemia | 1.862 |
| Gardasil 9 | Merck & Co. | HPV Vaccine | 1.637 |
| brexpiprazole | Otsuka Pharmaceutical and Lundbeck | schizophrenia and depression | 1.353 |
| Toujeo (new-formulation insulin glargine) | Sanofi | Diabetes | 1.265 |
| Cosentyx (secukinumab) | Novartis | psoriasis and psoriatic arthritis | 1.082 |
“This year’s forecast identifies a substantial increase in the number of predicted blockbusters, inviting discussion around the current status of the blockbuster model,” said Wendy Hamilton, global head of Life Sciences at Thomson Reuters. “As the pharmaceutical industry navigates constantly evolving revenue streams, this report serves as a valuable resource for identifying the therapies with the strongest sales potential.”
For more information about Thomson Reuters, please go to www.thomsonreuters.com.
Related topics
Related organisations
AbbVie, Bristol-Myers Squibb Company, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi
